Clinical Trial Update: An Phase III Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With PsO [Phase 3]

View source ↗

Summary

Phase III study update for a recombinant anti-IL-17A monoclonal antibody in Chinese patients with plaque psoriasis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• Recombinant anti-IL-17A humanized monoclonal antibody

Snippet

Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Conditions: Plaque Psoriasis Patients | Phase 3 | Status: UNKNOWN